+89.7%
GSK vs FCUV
-96.6%
+186.4%
-37.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | FCUV | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.3% | -1.7% | +0.4% | -1.3% |
| 7D | -3.1% | +47.5% | -50.7% | -3.1% |
| 30D | -0.9% | +26.8% | -27.7% | -0.9% |
| 3M | -4.2% | -42.3% | +38.1% | -4.2% |
| 6M | -1.6% | +31.4% | -33.0% | -1.5% |
| YTD | +2.6% | -86.1% | +88.7% | +2.7% |
| 1Y | +6.2% | -95.5% | +101.8% | +6.3% |
| 3Y | +55.0% | -99.3% | +154.3% | +55.2% |
| 5Y | +42.8% | -99.8% | +142.6% | +43.1% |
| 10Y | +102.1% | -98.9% | +201.0% | +103.4% |
| All | +89.7% | -96.6% | +186.4% | +95.0% |
Cumulative growth
Daily Returns
Daily percentage return beside FCUV.
Daily Out/Under-Performance
Portfolio return minus FCUV return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × FCUV return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded FCUV wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling